The effect of metformin on decreasing the severity of rheumatoid arthritis

The effect of metformin on decreasing activity and severity of rheumatoid arthritis disease (pilot study)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190916044787N1

Enrollment

Registered

2019-10-01

Start date

2019-04-04

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis. Rheumatoid arthritis, unspecified

Interventions

Intervention 1: Intervention group: Metformin (Najo Company, Iran) is given at a dose of 500 mg twice a day for 12 weeks. Intervention 2: Control group: Placebo (made in School of Pharmacy, Ahvaz Univ

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with moderate to high severity of rheumatoid arthritis based on the DAS28 scale

Exclusion criteria

Exclusion criteria: Duration of illness over 3 years There is significant kidney disorder that forbids from using metformin (GFR <30) Pregnancy Significant heart failure (EF <50%) Chronic hepatic impairment or acute liver failure Having diabetes or previous and recent use of metformin The last 3 months of anti-inflammatory drugs New drug added to control patient symptoms during treatment

Design outcomes

Primary

Measure	Time frame
Disease severity. Timepoint: At baseline and after treatment (12 weeks). Method of measurement: DAS28.;Erythrocyte sedimentation rate (ESR). Timepoint: At baseline and after treatment (12 weeks). Method of measurement: Western Green analysis.;Swollen joint count (SJC). Timepoint: At baseline and after treatment (12 weeks). Method of measurement: Examination and clinical judgment of the physician.;Tender joint count (TJC). Timepoint: At baseline and after treatment (12 weeks). Method of measurement: Examination and clinical judgment of the physician.;CRP. Timepoint: At baseline and after treatment (12 weeks). Method of measurement: Aagglutination test.	—

Measure

Time frame

Disease severity. Timepoint: At baseline and after treatment (12 weeks). Method of measurement: DAS28.;Erythrocyte sedimentation rate (ESR). Timepoint: At baseline and after treatment (12 weeks). Method of measurement: Western Green analysis.;Swollen joint count (SJC). Timepoint: At baseline and after treatment (12 weeks). Method of measurement: Examination and clinical judgment of the physician.;Tender joint count (TJC). Timepoint: At baseline and after treatment (12 weeks). Method of measurement: Examination and clinical judgment of the physician.;CRP. Timepoint: At baseline and after treatment (12 weeks). Method of measurement: Aagglutination test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSajedeh Igder

Ahvaz University of Medical Sciences

Drsajedehigder3393@gmail.com+98 61 3222 2114

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026